Description: Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Home Page: www.modernatx.com
MRNA Technical Analysis
200 Technology Square
Cambridge,
MA
02139
United States
Phone:
617 714 6500
Officers
| Name | Title |
|---|---|
| Dr. Noubar B. Afeyan Ph.D. | Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board |
| Mr. Stephane Bancel | CEO & Director |
| Dr. Stephen Hoge M.D. | Pres |
| Ms. Shannon Thyme Klinger | Chief Legal Officer & Corp. Sec. |
| Mr. Juan Andres | Pres of Strategic Partnerships & Enterprise Expansion |
| Mr. James M. Mock | Chief Financial Officer |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer |
| Dr. John V. W. Reynders Ph.D. | Chief Information Officer |
| Dr. Melissa J. Moore Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board |
| Ms. Lavina Talukdar CFA | Sr. VP & Head of Investor Relations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 32.4675 |
|---|---|
| Trailing PE: | 7.0502 |
| Price-to-Book MRQ: | 4.4617 |
| Price-to-Sales TTM: | 3.7224 |
| IPO Date: | 2018-12-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 3700 |